NASOPHARYNGEAL CARCINOMA (NPC)
Clinical trials for NASOPHARYNGEAL CARCINOMA (NPC) explained in plain language.
Never miss a new study
Get alerted when new NASOPHARYNGEAL CARCINOMA (NPC) trials appear
Sign up with your email to follow new studies for NASOPHARYNGEAL CARCINOMA (NPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to stop aggressive nose cancer from coming back
Disease control Not yet recruitingThis phase 2 trial tests whether the drug becotatug vedotin can prevent cancer from returning in 140 patients with high-risk nasopharyngeal carcinoma who have completed standard chemo-radiation. Participants are randomly assigned to receive the drug or standard care. The main goa…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE2 • Sponsor: Kai Hu • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New proton therapy trial aims to reduce side effects in nasopharyngeal cancer
Disease control Not yet recruitingThis Phase III trial will compare proton beam radiotherapy with standard photon radiotherapy in 504 patients with non-metastatic nasopharyngeal carcinoma. The goal is to see if proton therapy reduces toxic side effects and improves survival. Participants will be randomly assigned…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: NA • Sponsor: Guangzhou Concord Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Hard-to-Treat nasopharyngeal cancer: ivonescimab trial launches
Disease control Not yet recruitingThis phase 2 trial is testing a drug called ivonescimab in 42 people with a type of head and neck cancer (nasopharyngeal carcinoma) that has stopped responding to standard immunotherapy and chemotherapy. The drug is given every 3 weeks by IV. Researchers will measure how many pat…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immune booster: donor NK cells aim to cut cancer recurrence
Disease control Not yet recruitingThis trial tests whether adding natural killer (NK) cells from healthy donors to standard chemoradiotherapy can reduce the risk of cancer returning in people with advanced nasopharyngeal cancer. The study has two phases: first, finding the safest dose of NK cells, then testing th…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE1, PHASE2 • Sponsor: Singapore General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to shrink Hard-to-Treat throat cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining two drugs—scipibaimab and tislelizumab—can shrink tumors in people with recurrent or metastatic nasopharyngeal carcinoma that has worsened after first-line treatment. About 37 adults whose cancer has not responded to platinum chemotherap…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug aims to stop chemo side effect in nose and throat cancer
Disease control Not yet recruitingThis study tests whether the drug hetrombopag can prevent severe low platelet counts caused by chemotherapy in people with nasopharyngeal carcinoma. About 35 patients who already had low platelets during a previous chemo cycle will take hetrombopag tablets daily during their next…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Simple scope procedure may prevent radiation damage in recurrent nose cancer
Prevention Not yet recruitingThis study tests whether removing a thin layer of tissue (pseudomembrane) from the back of the nose using a scope can prevent radiation-induced tissue death in patients with recurrent nasopharyngeal cancer who have had repeat radiation. About 40 adults in China will undergo the p…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: NA • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:24 UTC
-
Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients
Symptom relief Not yet recruitingThis trial compares early versus delayed acupuncture to reduce dry mouth caused by chemoradiation in head and neck cancer patients. Participants receive acupuncture either during chemoradiation or after, and their dry mouth symptoms are tracked for a year. The goal is to find the…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: NA • Sponsor: National University Hospital, Singapore • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Taurine: a simple supplement to fight radiation mouth sores?
Symptom relief Not yet recruitingThis phase 2 trial tests whether taking taurine (a common amino acid) can prevent or reduce severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. 130 patients will take taurine pills or receive standard care starting 3 days before radiation until 1 …
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to unlock immune secrets of nasopharyngeal cancer
Knowledge-focused Not yet recruitingThis study will look at tissue samples from 600 people with nasopharyngeal carcinoma to understand how the tumor's immune environment changes over time. The goal is to find markers that predict how well immunotherapy will work and to identify new treatment targets. Participants m…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Could new scans revolutionize nasopharyngeal cancer care?
Knowledge-focused Not yet recruitingThis observational study will test whether two new types of PET/CT scans can more accurately stage nasopharyngeal carcinoma and predict how well patients respond to immunotherapy before treatment. About 732 participants aged 18-70 with newly diagnosed, untreated cancer will recei…
Matched conditions: NASOPHARYNGEAL CARCINOMA (NPC)
Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:41 UTC